source
- FDA extends safety review of mifepristone into next year, report due by March 2027The FDA announced that its ongoing safety evaluation of mifepristone, the primary medication used for medical abortions, will not be completed until next year. The agency expects to finish the saf…
- Tailored breast cancer care for older women gains momentum as researchers highlight age-specific tumor differencesOlder women represent a large share of breast cancer diagnoses, with nearly half of cases occurring in patients 65 or older and about one-fifth in those 75 and older. Despite these numbers, clinic…